Rome Therapeutics, Inc.

ReCode Therapeutics , on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the ro

Lightstone Ventures has closed its third fund – its largest to date – with $375m to fund early stage biopharmaceutical and medical technology companies after several successful exits via initial publi